Cargando…

Bumetanide Exposure Association with Alzheimer’s Disease Risk

BACKGROUND: To investigate whether exposure history to two common loop diuretics affects the risk of developing Alzheimer’s disease (AD) after accounting for socioeconomic status and congestive heart failure. METHODS: Individuals exposed to bumetanide or furosemide were identified in the Stanford Un...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graber-Naidich, Anna, Lee, Justin, Younes, Kyan, Greicius, Michael D., Le Guen, Yann, He, Zihuai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Journal Experts 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002844/ https://www.ncbi.nlm.nih.gov/pubmed/36909637 http://dx.doi.org/10.21203/rs.3.rs-2574215/v1

Ejemplares similares

Loop diuretics association with Alzheimer’s disease risk
por: Graber-Naidich, Anna, et al.
Publicado: (2023)

A Fast and Robust Strategy to Remove Variant-Level Artifacts in Alzheimer Disease Sequencing Project Data
por: Belloy, Michael E., et al.
Publicado: (2022)

A novel age-informed approach for genetic association analysis in Alzheimer’s disease
por: Le Guen, Yann, et al.
Publicado: (2021)

Temporal tau asymmetry spectrum influences divergent behavior and language patterns in Alzheimer`s disease
por: Younes, Kyan, et al.
Publicado: (2023)

APOE-ε4 and BIN1 increase risk of Alzheimer’s disease pathology but not specifically of Lewy body pathology
por: Talyansky, Seth, et al.
Publicado: (2023)

APOE-ε4 and BIN1 increase risk of Alzheimer’s disease pathology but not specifically of Lewy body pathology
por: Talyansky, Seth, et al.
Publicado: (2023)

APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry
por: Belloy, Michael E., et al.
Publicado: (2023)

Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease
por: Boyarko, Ben, et al.
Publicado: (2023)

The NKCC1 antagonist bumetanide mitigates interneuronopathy associated with ethanol exposure in utero
por: Skorput, Alexander GJ, et al.
Publicado: (2019)

Genome-wide analysis of common and rare variants via multiple knockoffs at biobank scale, with an application to Alzheimer disease genetics
por: He, Zihuai, et al.
Publicado: (2021)

Identification of putative causal loci in whole-genome sequencing data via knockoff statistics
por: He, Zihuai, et al.
Publicado: (2021)

Sex‐ and APOE‐specific genetic risk factors for late‐onset Alzheimer's disease: Evidence from gene–gene interaction of longevity‐related loci
por: Dato, Serena, et al.
Publicado: (2023)

Bumetanide: Metabolic alkalosis: case report
Publicado: (2021)

Improving genetic risk prediction across diverse population by disentangling ancestry representations
por: Gyawali, Prashnna K., et al.
Publicado: (2023)

Off-Label Use of Bumetanide for Brain Disorders: An Overview
por: Kharod, Shivani C., et al.
Publicado: (2019)

Bumetanide for autism: Open‐label trial in six children
por: Fernell, Elisabeth, et al.
Publicado: (2021)

Bumetanide for neonatal seizures: No light in the pharmacokinetic/dynamic tunnel
por: Kaila, Kai, et al.
Publicado: (2022)

Bumetanide Prevents Brain Trauma-Induced Depressive-Like Behavior
por: Goubert, Emmanuelle, et al.
Publicado: (2019)

GhostKnockoff inference empowers identification of putative causal variants in genome-wide association studies
por: He, Zihuai, et al.
Publicado: (2022)

A randomised controlled trial of bumetanide in the treatment of autism in children
por: Lemonnier, E, et al.
Publicado: (2012)

Bumetanide for autism: more eye contact, less amygdala activation
por: Hadjikhani, Nouchine, et al.
Publicado: (2018)

Failure of bumetanide to improve outcome after intracerebral hemorrhage in rat
por: Wilkinson, Cassandra M., et al.
Publicado: (2019)

Albumin human/bumetanide: Osmotic demyelination syndrome: case report
Publicado: (2020)

Recent Consanguinity and Outbred Autozygosity Are Associated With Increased Risk of Late-Onset Alzheimer’s Disease
por: Napolioni, Valerio, et al.
Publicado: (2021)

A retrospective evaluation of the efficacy of intravenous bumetanide and comparison of potency with furosemide
por: Nappi, Jean M.
Publicado: (2013)

Bumetanide As a Candidate Treatment for Behavioral Problems in Tuberous Sclerosis Complex
por: Vlaskamp, Chantal, et al.
Publicado: (2017)

Longitudinal Effects of Bumetanide on Neuro-Cognitive Functioning in Drug-Resistant Epilepsy
por: Gharaylou, Zeinab, et al.
Publicado: (2019)

Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders
por: Lemonnier, E, et al.
Publicado: (2017)

Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders
por: Lemonnier, E, et al.
Publicado: (2017)

Bumetanide Suppression of Angiogenesis in a Rat Model of Oxygen-Induced Retinopathy
por: Guzel, Sibel, et al.
Publicado: (2020)

Analgesic Effect of Bumetanide on Neuropathic Pain in Patients With Spinal Cord Injury
por: Nasirinezhad, Farinaz, et al.
Publicado: (2021)

A Wholistic View of How Bumetanide Attenuates Autism Spectrum Disorders
por: Delpire, Eric, et al.
Publicado: (2022)

The immuno-behavioural covariation associated with the treatment response to bumetanide in young children with autism spectrum disorder
por: Li, Qingyang, et al.
Publicado: (2022)

APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer’s Disease pathology
por: Chemparathy, Augustine, et al.
Publicado: (2023)

Bumetanide Enhances Phenobarbital Efficacy in a Rat Model of Hypoxic Neonatal Seizures
por: Cleary, Ryan T., et al.
Publicado: (2013)

Effect of Co-administration of Bumetanide and Phenobarbital on Seizure Attacks in Temporal Lobe Epilepsy
por: Rahmanzadeh, Reza, et al.
Publicado: (2018)

Single-case experimental designs for bumetanide across neurodevelopmental disorders: BUDDI protocol
por: Geertjens, Lisa, et al.
Publicado: (2022)

Bumetanide induces post-traumatic microglia–interneuron contact to promote neurogenesis and recovery
por: Tessier, Marine, et al.
Publicado: (2023)

Confirming Pathogenicity of the F386L PSEN1 Variant in a South Asian Family With Early-Onset Alzheimer Disease
por: Eger, Sarah J., et al.
Publicado: (2021)

Correction: Bumetanide Enhances Phenobarbital Efficacy in a Rat Model of Hypoxic Neonatal Seizures
por: Cleary, Ryan T., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_voegglfu0jlk1824kir4ib5k04